CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program Association between Coronary Collaterals and Myocardial Viability in Patients with a Chronic Total Occlusion Evaluation and Management of Nonculprit Lesions in STEMI 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Revascularization Strategies in STEMI with Multivessel Disease: Deciding on Culprit Versus Complete-Ad Hoc or Staged Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial Impact of tissue protrusion after coronary stenting in patients with ST-segment elevation myocardial infarction Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) The year in cardiovascular medicine 2020: acute coronary syndromes and intensive cardiac care Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry

Review Article2017 Apr;110(4):259-272

JOURNAL: Article Link

Contemporary use of drug-coated balloons in coronary artery disease: Where are we now?

Picard F, Doucet S, Asgar AW Keywords: Angioplastie percutanée; Athérosclérose; Ballon médicamenté; Drug-coated balloon; Drug-eluting balloon; In-stent restenosis; Paclitaxel; Percutaneous coronary intervention; Resténose intra-stent

ABSTRACT

The drug-coated balloon (DCB) has emerged as an additional tool in the arsenal of interventional cardiology devices; it delivers antiproliferative drugs to local arterial tissue by single prolonged coated balloon angioplasty inflation, and prevents restenosis, leaving no implant behind. This strategy theoretically decreases the risk of late inflammatory response to device components, without preventing positive remodelling. DCBs, when used carefully and with a good technique, may have a role in the treatment of lesion subsets, such as in-stent restenosis, small vessel disease or side branch bifurcations, in which the implantation of a drug-eluting stent is not desirable or is technically challenging. Using the latest evidence regarding the effectiveness of the currently available DCBs, this review will discuss the rationale for DCB use, and the effectiveness of DCBs in different clinical and lesion settings, and will give practical tips for their correct use in everyday clinical practice.